TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Tarsus Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$69.50+1.43 (+2.10%)
Close on Oct 19, 2026
- Market cap
- $3.02B
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Tarsus Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Tarsus Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $3.05B | $164.85M |
| Enterprise Value | $2.67B | $87.06M |
| PS Ratio | 5.03 | 3.60 |
| PB Ratio | 8.80 | 2.03 |
| P/TBV Ratio | 8.97 | 2.31 |
| P/FCF Ratio | 54.46 | 17.44 |
| P/OCF Ratio | 41.13 | 13.32 |
Enterprise value
| Measure | Tarsus Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 4.41 | 2.43 |
| EV / FCF | 47.73 | 20.97 |
Income (trailing twelve months)
| Measure | Tarsus Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $606.33M | $57.94M |
| Operating Income | -$48.54M | -$21.44M |
| Net Income | -$46.48M | -$22.46M |
| EBITDA | -$48.54M | -$16.91M |
| EPS (Diluted) | -$1.09 | -$0.83 |
Margins
| Measure | Tarsus Pharmaceuticals | Industry median |
|---|---|---|
| Operating Margin | -8.00% | -44.5% |
| Profit Margin | -7.67% | -39.2% |
| EBITDA Margin | -8.00% | -31.3% |
| FCF Margin | 9.24% | -8.85% |
Returns
| Measure | Tarsus Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -13.7% | -53.1% |
| Return on Assets (ROA) | -8.40% | -41.0% |
| Return on Capital Employed (ROCE) | -11.1% | -37.8% |
Growth
| Measure | Tarsus Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 105.2% | 6.01% |
| Revenue Growth (3Y CAGR) | 159.5% | 2.25% |
Balance sheet
| Measure | Tarsus Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $449.69M | $62.42M |
| Total Debt | $72.76M | $120.13M |
| Net Cash (Debt) | $376.93M | $15.68M |
| Net Cash Per Share | $8.59 | $0.66 |
| Equity (Book Value) | $346.73M | $48.79M |
| Book Value Per Share | $7.90 | $1.36 |
| Tangible Book Value | $339.85M | $23.06M |
| Working Capital | $386.24M | $75.77M |
Financial position
| Measure | Tarsus Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 3.20 | 3.30 |
| Quick Ratio | 3.11 | 2.39 |
| Debt / Equity | 0.21 | 0.51 |
| Debt / FCF | 1.30 | 5.05 |
| Interest Coverage | -5.54 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Tarsus Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | $74.16M | -$12.35M |
| Capital Expenditures | -$18.16M | -$1.06M |
| Free Cash Flow | $56.00M | -$20.28M |
| FCF Per Share | $1.28 | -$0.42 |
Efficiency
| Measure | Tarsus Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 1.10 | 0.38 |
| Revenue Per Employee | $1.64M | $398.96K |
| Profits Per Employee | -$125.61K | -$703.34K |
| Employee Count | 370 | 74 |
Dividends and yields
| Measure | Tarsus Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -1.52% | -22.7% |
| FCF Yield | 1.84% | -9.07% |
| Dividend Yield | 0.00% | 1.82% |
| Shareholder Yield | 0.00% | 0.00% |
| Dividend Per Share | $0.00 | $0.83 |
| Years of Dividend Growth | 0 | 0 |
Shares
| Measure | Tarsus Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 43,883,000 | 58,179,650 |
| Shares Change (YoY) | 8.24% | 11.1% |
| Shares Change (QoQ) | 0.58% | 0.54% |
| Float | 42,524,100 | 49,173,100 |
| Shares Held by Insiders | 3.10% | 11.6% |
| Shares Held by Institutions | 110.0% | 59.4% |
Scores
| Measure | Tarsus Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | 7.37 | -0.24 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Tarsus Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.